Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available.
On February 4, 2025, Mineralys Therapeutics announced the completion of enrollment for its Explore-CKD Phase 2 trial, which evaluates the efficacy and safety of lorundrostat for treating hypertension in patients with CKD and albuminuria. This trial aims to address poorly controlled hypertension, a major cause of renal failure and cardiovascular events, with results expected in the second quarter of 2025. This development marks a significant step in expanding treatment options for high-risk patients, potentially impacting the company’s competitive position in the market.
More about Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases driven by dysregulated aldosterone. The company’s primary product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for the treatment of cardiorenal conditions such as hypertension, CKD, and OSA.
YTD Price Performance: -15.92%
Average Trading Volume: 233,141
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $512.6M
See more data about MLYS stock on TipRanks’ Stock Analysis page.
